bioRxiv · 10.1101/454447
Evolutionary exploitation of PD-L1 expression in hormone receptor positive breast cancer
Abstract
Based on clinical data from hormone positive breast cancer patients, we determined that there is a potential tradeoff between reducing tumor burden and altering metastatic potential when administering combination therapy of aromatase inhibitors and immune checkpoint inhibitors. While hormone-deprivation therapies serve to reduce tumor size in the neoadjuvant setting pre-surgery, they may induce tumors to change expression patterns towards a metastatic phenotype. We used mathematical modeling to explore how the timing of the therapies affects tumor burden and metastatic potential with an eye toward developing a dynamic prognostic score and reducing both tumor size and risk of metastasis.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
West, J., Park, D., Harmon, C., Williamson, D., Ashcroft, P., Maestrini, D., Ardaseva, A., Bravo, R., Sahoo, P., Khong, H., Luddy, K., Robertson-Tessi, M.. 2018-10-26. Evolutionary exploitation of PD-L1 expression in hormone receptor positive breast cancer. https://doi.org/10.1101/454447
Cite the original work for its findings. Save a collection to share your selection of sources.